Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-A51 Monotherapy and with Azacitidine in AML/MDS
NCT04243785Phase 1Recruiting
- Sponsor
- Edgewood Oncology
- Start
- Jan 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BTX-A51 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Edgewood Oncology. Primary endpoints: Incidence of Dose-Limiting Toxicities up to 224 days, Number of participants with Adverse Events up to 224 days and 2 more. Started Jan 2020; status: recruiting.
02
Drugs
BTX-A51
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04243785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243785.